Alternative antiandrogens to treat androgen independent prostate cancer

Chinese Journal of Andrology

Volumn 22, Issue 4, 2008, Pages 32-36

  Shen, Yijun ^a   Ye, Dingwei ^a   Yao, Xudong ^a   Zhang, Shilin ^a   Dai, Bo ^a   Zhang, Hailiang ^a   Zhu, Yao ^a   Chen, Yu ^a   Ma, Chunguang ^a  

^a NONE

Author keywords

Prognosis; Prostatic neoplasms drug therapy

Indexed keywords

BICALUTAMIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; SURVIVAL TIME; WITHDRAWAL SYNDROME;

EID: 44849137887     PISSN: 10080848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 1997; 15(1): 382-388
2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513-1520
4. Daskivich TJ, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol 2006; 16(3): 173-178
5. OH WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002; 60(3 Suppl 1): 87-92
6. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355 (9214): 1491-1498
7. Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15(8): 2928-2938
8. Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159(1): 149-153
9. Kojima S, Suzuki H, Akakura K, et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171(2 Pt 1): 679-683
10. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005; 96(6): 791-795
11. Okihara K, Ukimura O, Kanemitsu N, et al. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007; 14(2): 128-132
12. Chinese source
13. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63(1): 149-153
14. Taplin ME, Rajeshkumar B, Halabi S, et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21(14): 2673-2678
15. Halabi S, Small EJ, Hayes DF, et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol 2003; 21(3): 490-495